Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing | Zendy

Kelly A. Johnson | Zendy; Xin Niu | Zendy; David V. Glidden | Zendy; José CastilloMancilla | Zendy; Jenna Yager | Zendy; Samantha MaWhinney | Zendy; Mary Morrow | Zendy; Hideaki Okochi | Zendy; Tim R. Cressey | Zendy; Paul K. Drain | Zendy; Monica Gandhi | Zendy; Peter L. Anderson | Zendy; Matthew A. Spinelli | Zendy

Open Access

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

Author(s) -

Kelly A. Johnson,

Xin Niu,

David V. Glidden,

José CastilloMancilla,

Jenna Yager,

Samantha MaWhinney,

Mary Morrow,

Hideaki Okochi,

Tim R. Cressey,

Paul K. Drain,

Monica Gandhi,

Peter L. Anderson,

Matthew A. Spinelli

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab200

Subject(s) - tenofovir alafenamide , medicine , tenofovir , urine , cobicistat , human immunodeficiency virus (hiv) , antiretroviral therapy , virology , viral load

From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research